Table 1.
Parameters describing the HIV cohort and the controls included in this study.
| Patient groups | HAART-naive (n = 20) | INRs (n = 20) | Responders (n = 20) | Controls (n = 20) |
|---|---|---|---|---|
| Characteristics | ||||
| Age, years (IQR) | 40·5 (34·3–52·8) | 52·0 (43·0–64·5) | 46·5 (43·0–51·0) | 47·5 (35·0–55·0) |
| Male (no.) | 17 | 14 | 12 | 16 |
| Female (no.) | 3 | 6 | 8 | 4 |
| CD4 cell count at inclusion date, median cells/μl (IQR) | 555 (385–743) | 320 (280–378) | 790 (640–1000) | – |
| Nadir CD4 cell count, median cells/μl (IQR) | 480 (385–613) | 63 (20–139) | 197 (119–340) | – |
| HIV-RNA level, median log (copies/ml) (IQR) | 4·2 (3·6–5·0) | – | – | – |
| Duration of HAART, median years (IQR) | – | 5·6 (4·4–7·2) | 10·1 (7·7–14·5) | – |
| Pre-viraemic index, median log (copies/ml) (IQR) | – | 4·9 (4·3–6·1) | 5·0 (4·7–5·8) | – |
INRs = immunological non-responders; IQR = interquartile range; HAART = highly active anti-retroviral therapy.